Vitamin C for kidney injury in severe liver failure with septic shock
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests whether giving high-dose vitamin C can help improve kidney function in people with severe liver failure, sudden kidney injury, and a serious infection with very low blood pressure. It's a randomized trial, meaning half the participants get vitamin C and half get a placebo, to see which group does better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have acute-on-chronic liver failure (a sudden worsening of an existing liver condition)
- You have acute kidney injury (sudden kidney damage) that meets certain medical criteria
- You have septic shock (a severe infection causing very low blood pressure)
- You are not in a situation where doctors have decided to limit life-support measures (like refusing ventilator or heart support)
- You do not have certain medical conditions like severe heart or lung disease, active bleeding, certain cancers, or kidney stones
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a blood-filtering system called CytoSorb in people with severe liver failure that also affects other organs. It aims to see if removing toxins from the blood can help reduce damage and improve recovery.
This study tests a treatment that cleans your blood to help your liver recover if you have sudden liver failure. It may improve your chances of getting better.
This Phase 2 study tests whether early high-dose vitamin C given through a vein can improve outcomes for people who remain unconscious after an out-of-hospital cardiac arrest with shock. It may help by supporting recovery during the time when the body is under severe stress.
This trial tests whether a combination of vitamins B6, B12, and C can help improve blood flow in tiny blood vessels (microcirculation) for people with sepsis. It may help your body recover better from severe infection.
This trial tests if adding an iron chelator (MEX-CD1) to the dialysis fluid can help remove harmful iron from the blood in patients with sepsis-related acute kidney injury who need continuous dialysis. It may reduce damage to the kidneys and other organs.
This trial studies two ways of giving albumin (a protein given through an IV) to people with cirrhosis who also have a sudden kidney injury from sepsis. The goal is to see which method—tailored to each patient or a fixed dose—is safer and works better for kidney recovery.
Hear when a new Acute-on-Chronic Liver Failure (ACLF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.